{"entity":{"id":"nct04205227","kind":"trial","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in melanoma, run by ENB Therapeutics, Inc, active and no longer recruiting.","summary":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors is a phase 1/2 interventional study registered as NCT04205227 by ENB Therapeutics, Inc, with 137 participants planned, started 2020-02-18 and due to reach its primary completion in 2026-01-01. Interventions recorded: ENB003, Pembrolizumab. Conditions listed: Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04205227","url":"https://clinicaltrials.gov/study/NCT04205227"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04205227","phase":"1/2","setting":"A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors","sponsor":"ENB Therapeutics, Inc","enrolled":137,"outcomes":[]},"route":"/trials/nct04205227/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}